Validez de la prueba de actividad enzimática de la glucocerebrosidasa para el diagnóstico de enfermedad de Gaucher, revisión sistemática

dc.contributor.authorVera Cala, Lina Maríaspa
dc.contributor.authorSerrano Gómez, Sergio Eduardospa
dc.contributor.authorCortés, Alexandraspa
dc.contributor.authorEstrada, Ismaelspa
dc.contributor.authorGáfaro, Auroraspa
dc.contributor.cvlacVera Cala, Lina María [0000091723]spa
dc.contributor.cvlacSerrano Gómez, Sergio Eduardo [0001521095]spa
dc.contributor.googlescholarVera Cala, Lina María [1KksmRYAAAAJ&hl=es&oi=ao]spa
dc.contributor.googlescholarSerrano Gómez, Sergio Eduardo [e0iMQ5oAAAAJ&hl=es&oi=ao]spa
dc.contributor.orcidVera Cala, Lina María [0000-0003-3174-8153]spa
dc.contributor.orcidSerrano Gómez, Sergio Eduardo [0000-0001-6418-7116]spa
dc.contributor.orcidSerrano Gómez, Sergio Eduardo [0000-0001-6418-7116]spa
dc.contributor.researchgroupGrupo de Investigaciones Clínicasspa
dc.date.accessioned2020-10-27T14:19:35Z
dc.date.available2020-10-27T14:19:35Z
dc.date.issued2017-08-04
dc.description.abstractIntroducción: La enfermedad de Gaucher es un trastorno metabólico por deficiencia o ausencia de enzima β-Glucosidasa Ácida. El diagnóstico se sospecha clínicamente, pero requiere confirmación mediante medición, en leucocitos (estándar de oro) o en sangre seca sobre papel de filtro, de la actividad de la enzima β-Glucosidasa Ácida. Objetivo: Evaluar la validez de la medición de la actividad de la enzima β-Glucosidasa Ácida en sangre seca en papel de filtro, comparada con el estándar de oro, para el diagnóstico de enfermedad de Gaucher en pacientes con sospecha clínica. Metodología: Se hizo una revisión sistemática de literatura. Se construyó y validó una pregunta PICO. Se usó una estrategia de búsqueda genérica con base en los términos clave (Gaucher Disease y Dried Blood Spot Analysis). Dos evaluadores independientes revisaron, evaluaron la calidad y extrajeron la información de los artículos. Resultados: Descartando los duplicados, se obtuvieron 47 artículos. Se evaluaron los textos completos de cuatro, y tres de ellos fueron excluidos al aplicar criterios de inclusión y exclusión. El artículo incluido tuvo una calidad excelente y mostró que la actividad enzimática de la glucocerebrosidasa en sangre seca tuvo sensibilidad de 82.3% y especificidad de 94.0% con un punto de corte de 0.0-2.75 y sensibilidad de 88.2% y especificidad de 88.5% con un punto de corte de 0.0-4.4. Conclusiones: La medición enzimática de la β-glucosidasa ácida en sangre seca es una excelente prueba para diagnóstico inicial de enfermedad de Gaucher. Sin embargo, no es una prueba concluyente. [Vera-Cala LM, Serrano-Gómez SE, Córtes A, Estrada I, Gáfaro A. Validez de la prueba de actividad enzimática de la glucocerebrosidasa para el diagnóstico de enfermedad de Gaucher, revisión sistemática. MedUNAB 2017; 20(2): 201-206].spa
dc.description.abstractenglishIntroduction: The Gaucher disease is a metabolic disorder due to deficiency or absence of acid β-glucosidase enzyme. The diagnosis is clinically suspected, but requires confirmation by measuring the activity of acid β-glucosidase enzyme in leukocytes (gold standard) or in dried blood on filter paper. Objective: To assess the validity of the measurement of acid β-glucosidase enzyme activity in dried blood on filter paper compared to the standard of gold, for the diagnosis of Gaucher disease in patients with clinical suspicion. Methodology: A systematic review of literature was carried out. A PICO question was constructed and validated. A generic search strategy was used based on the key terms (Gaucher Disease and Dried Blood Spot Analysis). Two independent evaluators reviewed and assessed the quality, and extracted information from the articles. Results: Discarding the duplicates, 47 articles were obtained. Four complete texts were evaluated, and three of them were excluded when applying inclusion and exclusion criteria. The article that was included had an excellent quality and showed that the enzymatic activity of glucocerebrosidase in dried blood had a sensitivity of 82.3%, a specificity of 94.0% with a cut-off of 0.0-2.75, a sensitivity of 88.2% and specificity of 88.5% with a cut-off point of 0.0-4.4. Conclusions: The enzymatic measurement of acid β-glucosidase in dried blood is an excellent test for an initial diagnosis of Gaucher disease; however, it is not a conclusive proof. [Vera-Cala LM, Serrano-Gómez SE, Córtes A, Estrada I, Gáfaro A. Validity of the Enzymatic Activity Test of Glucocerebrosidase for the Diagnosis of Gaucher Disease, a Systematic Review. MedUNAB 2017; 20(2): 201-206].eng
dc.format.mimetypeapplication/pdfspa
dc.identifier.doi10.29375/01237047.3247
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga UNABspa
dc.identifier.issn2382-4603
dc.identifier.issn0123-7047
dc.identifier.repourlrepourl:https://repository.unab.edu.co
dc.identifier.urihttp://hdl.handle.net/20.500.12749/9997
dc.language.isospaspa
dc.publisherUniversidad Autónoma de Bucaramanga UNAB
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.programPregrado Medicinaspa
dc.relationhttps://revistas.unab.edu.co/index.php/medunab/article/view/3247/2805
dc.relation/*ref*/Deegan P, Hughes D, Cox T. UK National Guideline for Adult Gaucher Disease. 2005. 2. Manger B, Menge E, Schaefer R, Haase C, Seidel J, Michels H. Gaucher disease, Fabry disease and mucopolysaccharidosis type I--how can the rheumatologist recognise these patients?. Z Rheumatol. 2006; 65(1):34–43. 3. Franco-Ornelas S. Mexican consensus on Gaucher’s disease. Rev Med Inst Mex Seguro Soc. 2010; 48(2):167–86. 4. Mehta A. Epidemiology and natural history of Gaucher’s disease. Eur J Intern Med. 2006; 17 Suppl:S2–5. 5. Uribe A, Giugliani R. Selective screening for lysosomal storage diseases with dried blood spots collected on filter paper in 4,700 high-risk colombian subjects. JIMD Rep. 2013; 11:107–16. 6. Sidransky E. Gaucher disease: complexity in a “simple” disorder. Mol Genet Metab. 2004; 83(1-2):6–15. 7. Fundación Española de Enfermedades Lisosomales. Actualización en Enfermedad de Gaucher [Internet]. 2008 [cited 2014 Aug 8]. Disponible en: http://www.fundacionlisosomales.es/wp-content/uploads/2009/07/MEMORIA-FEEL- 8. Bodamer OA, Hung C. Laboratory and genetic evaluation of Gaucher disease. Wien Med Wochenschr. 2010; 160(23-24):600–4. 9. Elbin CS, Olivova P, Marashio CA, Cooper SK, Cullen E, Keutzer JM, et al. The effect of preparation, storage and shipping of dried blood spots on the activity of five lysosomal enzymes. Clin Chim Acta. 2011; 412(13-14):1207–12. 10. The Cochrane Collaboration. Handbook for DTA Reviews [Internet]. 2013 [cited 2014 Sep 10]. Disponible en: http://srdta.cochrane.org/handbook-dta-reviews 11. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529–36. 12. Whiting P, Rutjes AWS, Reitsma JB, Bossuyt PMM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003; 3(1)3:25. 13. Goldim MP de S, Garcia C da S, de Castilhos CD, Daitx VV, Mezzalira J, Breier AC, et al. Screening of high-risk Gaucher disease patients in Brazil using miniaturized dried blood spots and leukocyte techniques. Gene. 2012; 508(2):197–8. 14. Chaves RG, Coelho JC, Michelin-Tirelli K, Maurício TF, de Freitas Maia Chaves E, de Almeida PC, et al. Successful screening for Gaucher disease in a high-prevalence population in tabuleiro do Norte (northeastern Brazil): a cross-sectional study. JIMD Rep. 2011; 1:73–8. 15. Stroppiano M, Calevo MG, Corsolini F, Cassanello M, Cassinerio E, Lanza F, et al. Validity of β-d-glucosidase activity measured in dried blood samples for detection of potential Gaucher disease patients. Clin Biochem. 2014; 47(13-14):1293-96.
dc.relation.referencesDeegan P, Hughes D, Cox T. UK National Guideline for Adult Gaucher Disease. 2005spa
dc.relation.referencesManger B, Menge E, Schaefer R, Haase C, Seidel J, MichelsH.Gaucherdisease,Fabrydiseaseand mucopolysaccharidosistypeI--howcanthe rheumatologist recognise these patients?. Z Rheumatol. 2006; 65(1):34–43spa
dc.relation.referencesFranco-Ornelas S. Mexican consensus on Gaucher's disease.RevMedInstMexSeguroSoc.2010; 48(2):167–86.spa
dc.relation.referencesMehta A. Epidemiology and natural history of Gaucher's disease. Eur J Intern Med. 2006; 17 Suppl:S2–5spa
dc.relation.referencesUribe A, Giugliani R. Selective screening for lysosomal storage diseases with dried blood spots collected on filter paper in 4,700 high-risk colombian subjects. JIMDRep. 2013; 11:107–16.spa
dc.relation.referencesSidransky E. Gaucher disease: complexity in a “simple” disorder. Mol Genet Metab. 2004; 83(1-2):6–15spa
dc.relation.referencesFundación Española de Enfermedades Lisosomales. Actualización en Enfermedad de Gaucher [Internet]. 2008[cited2014Aug8].Disponibleen: http://www.fundacionlisosomales.es/wp-content/uploads/2009/07/MEMORIA-FEELspa
dc.relation.referencesBodamerOA,HungC.Laboratoryandgenetic evaluation of Gaucher disease. Wien Med Wochenschr. 2010; 160(23-24):600–4spa
dc.relation.referencesElbin CS, Olivova P, Marashio CA, Cooper SK, Cullen E, Keutzer JM, et al. The effect of preparation, storage and shipping of dried blood spots on the activity of five lysosomal enzymes. Clin Chim Acta. 2011; 412(13-14):1207–12spa
dc.relation.referencesTheCochraneCollaboration.HandbookforDTAReviews [Internet]. 2013 [cited 2014 Sep 10]spa
dc.relation.referencesWhiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool forthequalityassessmentofdiagnosticaccuracy studies. Ann Intern Med. 2011; 155(8):529–36spa
dc.relation.referencesWhiting P, Rutjes AWS, Reitsma JB, Bossuyt PMM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy includedinsystematicreviews.BMCMedRes Methodol. 2003; 3(1)3:25spa
dc.relation.referencesGoldim MP de S, Garcia C da S, de Castilhos CD, Daitx VV, Mezzalira J, Breier AC, et al. Screening of high-risk Gaucher disease patients in Brazil using miniaturized dried blood spots and leukocyte techniques. Gene. 2012; 508(2):197–8spa
dc.relation.referencesChaves RG, Coelho JC, Michelin-Tirelli K, Maurício TF, deFreitasMaiaChavesE,deAlmeidaPC,etal. Successful screening for Gaucher disease in a high-prevalencepopulationintabuleirodoNorte (northeastern Brazil): a cross-sectional study. JIMDRep. 2011; 1:73–8spa
dc.relation.referencesStroppiano M, Calevo MG, Corsolini F, Cassanello M, Cassinerio E, Lanza F, et al. Validity of β-d-glucosidase activity measured in dried blood samples for detection of potential Gaucher disease patients. Clin Biochem. 2014; 47(13-14):1293-96spa
dc.relation.urihttps://revistas.unab.edu.co/index.php/medunab/article/view/3247
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.sourceMedUNAB; Vol. 20 Núm. 2 (2017): Agosto - Noviembre de 2017: Prevención de Caídas, Educación Médica, Leishmaniasis Cutánea; 201-206
dc.subject.keywordsGaucher diseaseeng
dc.subject.keywordsDried blood spot testingeng
dc.subject.keywordsLeukocyteseng
dc.subject.keywordsSensitivity and specificityeng
dc.subject.keywordsDiagnosiseng
dc.subject.keywordsGlucosylceramidaseeng
dc.subject.lembCiencias de la saludspa
dc.subject.lembMedicinaspa
dc.subject.lembCiencias medicasspa
dc.subject.proposalEnfermedad de Gaucherspa
dc.subject.proposalPruebas con sangre secaspa
dc.subject.proposalLeucocitosspa
dc.subject.proposalSensibilidad y especificidadspa
dc.subject.proposalDiagnósticospa
dc.subject.proposalGlucosilceramidasaspa
dc.titleValidez de la prueba de actividad enzimática de la glucocerebrosidasa para el diagnóstico de enfermedad de Gaucher, revisión sistemáticaspa
dc.title.translatedValidity of the enzymatic activity test of glucocerebrosidase for the diagnosis of Gaucher disease, a systematic revieweng
dc.type.coarhttp://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversionInfo:eu-repo/semantics/publishedVersion
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.type.localArtículospa
dc.type.redcolhttp://purl.org/redcol/resource_type/ART

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
2017_Validez_de_la_prueba_de_actividad.pdf
Tamaño:
869.44 KB
Formato:
Adobe Portable Document Format
Descripción:
Articulo